We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2020) 203(1):73-82. PMID: 31389764
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267
DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904
I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce mortality and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.
Our past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
There are currently two main research areas of interest:
AtlFast3: The Next Generation of Fast Simulation in ATLAS Aad G, Abbott B, Abbott DC et al. Computing and Software for Big Science (2022) 6(7)
Emulating the impact of additional proton–proton interactions in the ATLAS simulation by presampling sets of inelastic Monte Carlo events Aad G, Abbott B, Abbott DC et al. Computing and Software for Big Science (2022) 6(7)
Measurement of the energy response of the ATLAS calorimeter to charged pions from W±→τ±(→π±ντ)ντ events in Run 2 data Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 223
The ATLAS inner detector trigger performance in pp collisions at 13 TeV during LHC Run 2 Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 206
Search for Higgs bosons decaying into new spin-0 or spin-1 particles in four-lepton final states with the ATLAS detector with 139 fb−1 of pp collision data at s = 13 TeV Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2022) 2022(10) 41
Observation of electroweak production of two jets in association with an isolated photon and missing transverse momentum, and search for a Higgs boson decaying into invisible particles at 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(10) 105
Performance of the ATLAS Level-1 topological trigger in Run 2 Aad G, Abbott B, Abbott DC et al. European Physical Journal C: Particles and Fields (2022) 82(1)
Measurement of the c-jet mistagging efficiency in tt¯ events using pp collision data at √s=13 TeV collected with the ATLAS detector Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2022) 82(7)
Search for exotic decays of the Higgs boson into b b¯ and missing transverse momentum in pp collisions at √s = 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2022) 2022(7)
Erratum to: Measurement of hadronic event shapes in high-pT multijet final states at s = 13 TeV with the ATLAS detector Aad G, Abbott B, Abbott DC et al. Journal of High Energy Physics (2021) 2021(10) 53
For additional publications, please click herePostdoctoral Researchers
PhD Students
Clinical Research Fellows
Research Technician
Education
Appointments